Kyongbo Pharmaceutical Co., Ltd

KOSE:A214390 Stock Report

Market Cap: ₩129.1b

Kyongbo Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Kyongbo Pharmaceutical has been growing earnings at an average annual rate of 26.5%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 8.6% per year. Kyongbo Pharmaceutical's return on equity is 0.2%, and it has net margins of 0.1%.

Key information

26.51%

Earnings growth rate

26.18%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate8.56%
Return on equity0.24%
Net Margin0.13%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Nov 18

Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...

Recent updates

Analysis Article • Sep 24

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Shares Climb 27% But Its Business Is Yet to Catch Up

Kyongbo Pharmaceutical Co., Ltd ( KRX:214390 ) shareholders have had their patience rewarded with a 27% share price...
Analysis Article • Sep 11

Does Kyongbo Pharmaceutical (KRX:214390) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 19

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Business Is Trailing The Market But Its Shares Aren't

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 12x, you may consider...
Analysis Article • Feb 19

Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Investors Are Less Pessimistic Than Expected

Kyongbo Pharmaceutical Co., Ltd's ( KRX:214390 ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...
Analysis Article • Mar 09

Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 02

What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?

The big shareholder groups in Kyongbo Pharmaceutical Co., Ltd ( KRX:214390 ) have power over the company. Large...
Analysis Article • Jan 12

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Kyongbo Pharmaceutical's (KRX:214390) stock is up by a considerable 42% over the past three months. However, we decided...
Analysis Article • Dec 25

Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
Analysis Article • Dec 08

Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 18

Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...

Revenue & Expenses Breakdown

How Kyongbo Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A214390 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26269,64234780,12118,313
31 Dec 25264,10418277,45918,158
30 Sep 25252,2012,35674,85817,011
30 Jun 25243,44540671,39914,923
31 Mar 25236,5442,29564,82616,937
31 Dec 24238,5564,63963,80812,166
30 Sep 24240,5104,92554,52712,468
30 Jun 24236,8614,60853,37310,100
31 Mar 24231,0045,36454,9573,654
31 Dec 23216,3572,97450,7753,654
30 Sep 23212,9022,36146,8363,077
30 Jun 23207,6511,64143,3043,077
31 Mar 23201,204-28939,7453,077
31 Dec 22196,26561136,6873,077
30 Sep 22180,396-3,89933,7695,053
30 Jun 22170,024-8,48733,5025,053
31 Mar 22169,982-8,85433,5005,053
31 Dec 21170,660-7,49533,4815,053
30 Sep 21177,259-4,07233,5406,238
30 Jun 21193,0372,93734,1606,238
31 Mar 21207,1728,91733,4356,238
31 Dec 20215,2859,40433,9356,238
30 Sep 20215,3487,25037,6911,418
30 Jun 20205,9076,23234,5881,418
31 Mar 20198,5975,13432,9661,418
31 Dec 19191,7065,28530,3971,418
30 Sep 19196,17110,07930,108770
30 Jun 19201,16610,92031,622374
31 Mar 19198,99811,23129,720770
31 Dec 18201,34413,11629,036770
30 Sep 18196,80514,44329,56387
30 Jun 18193,14717,74027,176593
31 Mar 18193,55518,49427,727507
31 Dec 17191,66117,96327,184765
30 Sep 17186,98017,08227,3051,253
30 Jun 17187,22312,70426,4961,355
31 Mar 17187,21611,81726,0821,371
31 Dec 16186,72612,70624,9341,484
30 Sep 16188,60419,61123,6911,337
30 Jun 16187,02523,49622,5301,659
31 Mar 16179,56125,51820,7071,724
31 Dec 15178,03326,11019,3671,867
30 Sep 15177,8354,23320,2151,942
30 Jun 15173,6683,31521,1341,829

Quality Earnings: A214390 has high quality earnings.

Growing Profit Margin: A214390's current net profit margins (0.1%) are lower than last year (1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A214390's earnings have grown significantly by 26.5% per year over the past 5 years.

Accelerating Growth: A214390's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A214390 had negative earnings growth (-84.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.5%).

Return on Equity

High ROE: A214390's Return on Equity (0.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/07 03:05
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyongbo Pharmaceutical Co., Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Seung-Ho LeeNH Investment & Securities Co., Ltd.